Keywords
Autoantígenos
Inmunoterapia
Anticuerpos antineoplásicos
Linfocitos T reguladores
Antígenos tumorales AIRE genes
Autoantigens
Immunotherapy
Antineoplasic antibodies
Regulatory T cells
Tumoral antigens
How to Cite
Abstract
The T cells in our immune system are able to recognize potential threats to both extrinsic and intrinsic antigens, some of these cells have some degree of reactivity against autoantigens enabling them to modulate the immune response against cells themselves (thereby regulating the trigger of autoimmunity) and against neoplastic cells (as an essential part of the anti-tumoral response). This group of cells, known under the category of regulatory T cells (Treg) are up-regulated by the gene expression, typically being described the relationship with the AIRE group of genes, that codifies the expression of transcription factors (essential to their immunoregulatory functions). Recently, there had been described two possible ways for this regulation through AIRE genes, AIRE-dependent and AIRE-independent, and with the knowledge of both of these molecular pathways could be plausible to inhibit or overstimulate its expression, being the key to improve anticancer immunotherapy. This paper reviews the theoretical basis of these Treg-cell-mediated antitumoral therapies.
References
Savage PA, Malchow S, Leventhal DS. Shaping the repertoire of tumor-infiltrating effector and regulatory T cells. Inmunol Rev. 2014 May. 259(1): 245-258. https://doi.org/10.1111/imr.12166
Baas M, Besancon A, Goncalves T, et al. TGFβ-dependent expression of PD-1 and PD-L1 controls CD8+T cell anergy in transplant tolerance. eLife. 2016; 5: e08133. https://doi.org/10.7554/eLife.08133
Saito K, Pignon P, Ayyoub M, Valmori D. Modulation of Cytokine Secretion Allows CD4 T Cells Secreting IL-10 and IL-17 to Simultaneosly Participate in Maintaining Tolerance and Immunity. PlosONE. 2015. 10.1371/journal.pone.0145788. https://doi.org/10.1158/2326-6074.CRICIMTEATIAACR15-B056
Nova-Lamperti E, Fanelli G, Hernández-Fuentes MP, et al. IL-10-produced by human transitional B-cells down regulates CD86 expression on B-cells leading to inhibition of CD4+T-cell respones. Sci Rep. 2016; 6:20044. https://doi.org/10.1038/srep20044
Savage PA, Malchow S, Leventhal DS. Basic principles of tumor-associated regulatory T cell biology. Trends in Immunology. 2012 Sep. https://doi.org/10.1016/j.it.2012.08.005
Bennett CL, Christie J, Ramsdell F, et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet. 2001; 27(1): 20-21. https://doi.org/10.1038/83713
Gavin MA, Togerson TR, Houston E, et al. Single-cell analysis of normal and FOXP3-mutant human T cells: FOXP3 expression without regulatory T cell development. Proc Natl Acad Sci U S A. 2006; 103(17): 6659-666. https://doi.org/10.1073/pnas.0509484103
Renkvist N, Castelli C, Pamiani G. A listing of human tumor recognized by T cells. 2015 Jun (7): 4.
Van der Bruggen P, Traversari C, Chomez P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 1991 Dec 13. 254: 1643. https://doi.org/10.1126/science.1840703
Boël, P., C. Wildmann, M.-L. Sensi, R. Brasseur, J.-C. Renauld, P. Coulie, T. Boon, and P. van der bruggen. 1995. BAGE, anew gene enconding antigen recognized on human melanomas by cytolic T lymphocytes. Inmunity. 2 :167-175 https://doi.org/10.1016/S1074-7613(95)80053-0
Brasseur, F.,D. rimoldi, D, Liénard, B. Lethé, S. Carrel, F. Arenti, L. Suter, R. Vanwijck,A. Bourlond, Y. Humblet, A. Vaccas, et al. 1995. Expression of MAGE genes in primary and metastatic cutaneous melanoma. Int. J. Cancer. 56 :826-829
Gaugler, B., B. Van den Eynde, P. van der Bruggen, P. Romero, J.J. Gafotio, E. De plaen, B. Lethé, F. Brasseur, and T. Boon. 1994. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J. Exp. Med. 170 ;921-930 https://doi.org/10.1084/jem.179.3.921
HUGO Gene Nomenclature Committee. Artículos genes: AIRE, MAGE, BAGE, GAGE. Fecha de consulta: 11 de febrero de 2016.
Hewitt HB, Blake ER, Walder AS. A critique of the evidence for active host defense against cancer, based on personal studies of 27 murine tumors of spontaneous origin. Br J Cancer. 1976 Mar.33:241. https://doi.org/10.1038/bjc.1976.37
Boon, T., van der Bruggen, P. Human tumor antigens recognized by T lymphocytes. The Journal of experimental medicine, 1996; 183(3), 725-729. https://doi.org/10.1084/jem.183.3.725
Yee C, Savage PA, Lee PP, et al. Isolation of high avidity melanoma- reactive CTL from heterogeneous populations using peptide-MHC tetramers. J Immunol. 1999 Feb 15. 162: 2227.
Tsai, V., I. Kawashima, E. Keogh, K. Daly, A. Sette, E. Celis. 1998. In vitro immunization and expansion of antigen-specific cytotoxic T lymphocytes for adoptive immunotherapy using peptide-pulsed dendritic cells. Crit. Rev. Immunol. 18: 65 https://doi.org/10.1615/CritRevImmunol.v18.i1-2.80
Romero P, et al. Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes. J Exp Med. 1998 Nov 2.188:1641. https://doi.org/10.1084/jem.188.9.1641
Chan IH, Wu V, McCauley S, Grimm EA, Mumm JB. IL-10: Expanding the Immune Oncology Horizon. Receptors & clinical investigation. 2015;2(4):1041.
Perniola R, Musco G. The biophysical and biochemical properties of the autoimmune regulator (AIRE) protein. Biochim Biophys Acta. 2014 Feb; 1842(2): 326-37. https://doi.org/10.1016/j.bbadis.2013.11.020
Ferrone S, Marincola FM. Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. Immunol Today. 1995; 16: 487-494. https://doi.org/10.1016/0167-5699(95)80033-6
Kvistborg P, et al. TIL therapy broadens the tumor-reactive CD8 (+) T cell compartment in melanoma patients. Oncoimmunology. 2012 Jul 1.1:409. https://doi.org/10.4161/onci.18851
Andersen RS, et al. Dissection of T-cell antigen specificity in human melanoma.Cancer Res. 2012 Apr 1.72:1642. https://doi.org/10.1158/0008-5472.CAN-11-2614
Su MA, et al. Mechanisms of an autoimmunity syndrome in mice caused by a dominant mutation in AIRE. J Clin Invest. 2008 May.118:1712. https://doi.org/10.1172/JCI34523
Kuroda N, et al. Development of autoimmunity against transcriptionally unrepressed target antigen in the thymus of AIRE-deficient mice. J Immunol. 2005 Feb 15.174:1862." https://doi.org/10.4049/jimmunol.174.4.1862